Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma

Kohei Miyata1,2,3,4, Fusanori Yotsumoto2,3, Sung Ouk Nam1,3, Takashi Odawara5, Sadao Manabe5, Toyokazu Ishikawa5, Hiroaki Itamochi6, Junzo Kigawa7, Shuji Takada4, Hiroshi Asahara4,8, Masahide Kuroki2,3 & Shingo Miyamoto1,3

1Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
2Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
3Central Research Institute for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan
4Department of Systems BioMedicine, National Research Institute for Child Health and Development, Tokyo, Japan
5Kanaji Institute Research Foundation for Microbial Diseases of Osaka University, Kagawa, Japan
6Department of Obstetrics and Gynecology, Tottori University School of Medicine, Tottori, Japan
7Department of Cancer Center, Tottori University Hospital, Tottori, Japan
8Department of Systems BioMedicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Keywords
Chemotherapy, gene transcriptional regulation, HB-EGF, ovarian cancer

Abstract
Ovarian clear cell carcinoma (OCCC) is a worst histological subtype than other ovarian malignant tumor. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a promising target for ovarian cancer therapy. The aims of this study were to validate the efficacy of HB-EGF–targeted therapy for OCCC and to identify the transcription factor that contributed to the induction of HB-EGF by SN38 treatment in OCCC cells. HB-EGF was highly expressed in OCCC cells, and an increase of HB-EGF was induced by SN38 which had only antitumor effect among conventional anticancer agents on OCCC. A specific inhibitor of HB-EGF, a cross-reacting material 197 (CRM197), led to a synergistic increase in the number of apoptotic OCCC cells with the treatment of SN38. The luciferase assay with 5′-deletion promoter constructs identified a GC-rich element between −125 and −178 (the distal transcription start site was denoted +1) as a cis-regulatory region, and the treatment of SN38 induced luciferase activity in this region. An in silico and chromatin immunoprecipitation analysis estimated that SP1 bound to the cis-regulatory region of HB-EGF in OCCC cells. Real-time PCR and cell viability assays showed that the transfection of a small interfering RNA targeting SP1 suppressed the expression of HB-EGF induced by SN38, resulting in the enhanced sensitivity of SN38. Taken together, these results indicate that induction of HB-EGF expression contributed to defense mechanism against treatment of SN38 through the transcriptional activity of SP1 in OCCC cells.

Introduction
Ovarian cancer is the most lethal gynecological cancer in the Western world. Ovarian cancer usually has a poor prognosis because many cases are diagnosed in advanced stages. Standard treatment involves surgery, followed by chemotherapy including platinum derivatives (e.g., cisplatin [CDDP] or carboplatin) and taxanes (e.g., paclitaxel [PTX] or docetaxel). However, the 5-year survival rate of patients with advanced ovarian cancer has remained for the past three decades [1]. Ovarian clear cell carcinoma (OCCC), which is a common histological type in Japanese, is known to indicate significant drug resistance for conventional anticancer agents, resulting in a poorer prognosis. Moreover, the occurrence of OCCC, which links to endometriosis, has rapidly increased.
throughout the world [2]. Therefore, a new strategy for OCCC therapy has been highly anticipated [2].

Heparin-binding epidermal growth factor-like growth factor (HB-EGF), which belongs to the EGF family, is synthesized as an 87 amino acid membrane-anchored glycoprotein [3–5]. Cleavage of membrane-anchored HB-EGF by proteases, called “ectodomain shedding,” induces the secretion of soluble mature form of HB-EGF from the cell surface. Through ectodomain shedding, HB-EGF contributes to several biological processes, such as wound healing [6], inflammation [7, 8], embryogenesis [9], and carcinogenesis [10]. In previous reports, we described that the expression of HB-EGF was higher than that of other EGF ligands in the ascites and tissues of ovarian cancer patients [11, 12]. However, the molecular mechanism(s) underlying the increase of HB-EGF expression in ovarian cancer has remained unclear.

There have been several reports that have described other molecular mechanisms affecting the expression of HB-EGF. For example, inflammatory cytokines, including tumor necrosis factor-α and interleukin-1β, directly or indirectly activated the transcription of HB-EGF [13, 14]. In bladder cancer cells, insulin induces the transcriptional activation of epieregulin, HB-EGF, and amphiregulin (AREG), which may be regulated by transcriptional factors including specific protein 1 (SP1), activator protein-1 (AP-1), and nuclear factor-kappa B (NF-κB) [15]. HB-EGF was rapidly induced following exposure to a variety of chemotherapeutic agents, and the chemotherapeutic-induced HB-EGF expression was largely dependent on AP-1 and NF-κB [16]. In addition, transcription factors including SP1, AP-1, pancreatic and duodenal homeobox-1 (PDX-1), and myogenic differentiation 1 (MyoD) were detected as direct regulators of HB-EGF expression [15, 17–19]. However, the molecule(s) directly involved in the transcript of HB-EGF has remained unknown in human cancer.

The aim of this study is to assess the association between HB-EGF expression and the cell viability of OCCC cells. Additionally, in order to elucidate transcriptional regulation of HB-EGF in OCCC cells, we also performed a screening assay and identified the transcription factor, SP1, which is responsible for the upregulation of HB-EGF induced by anticancer agent.

Materials and Methods

Cells and cell culture

Eleven OCCC cell lines (RMG-I, RMG-II, OVISE, OVTOKO, KK, TU-OC-1, KOC-7C, HAC-2, OVAS, SMOV-2, ES-2) and 293T cells were used for the studies. The KK cells were a kind gift from Professor Yoshihiro Kikuchi, National Defense Medical College, Japan; the OVAS cells were provided by Professor Hiroshi Minaguchi, Yokohama City University, Japan; KOC-7C by Dr. Toru Sugiyama, Kurume University, Japan; SMOV-2 by Dr. Tomohiro Iida, St. Marianna University, Japan; and HAC-2 by Dr. Masato Nishida, Tsukuba University, Japan. TU-OC-1 cells were derived as described previously [20]. ES-2 cells were purchased from Summit Pharmaceuticals International Corporation (Tokyo, Japan). RMG-I, RMG-II, OVISE, OVTOKO, and 293T cells were purchased from the Health Science Research Resources Bank (HSRRB, Osaka, Japan). All OCCC cell lines were maintained in RPMI-1640 medium (Gibco, Carlsbad, CA), and 293T cells were maintained in DMEM medium (Gibco). The culture media were supplemented with 10% fetal bovine serum (FBS) (ICN Biomedical, Irvine, CA).

Cell viability and apoptosis assay

Paclitaxel (PTX), cisplatin (CDDP), and SN38 (the active metabolite of irinotecan) were purchased from Sigma-Aldrich (St. Louis, MO). Recombinant human HB-EGF (rhHB-EGF) was purchased from R&D systems (Minneapolis, MN). Cross-reactive material 197 (CRM197), a specific inhibitor of HB-EGF, was prepared as described previously [21]. In the cell viability assay, 20,000–40,000 cells were incubated in RPMI-1640 medium with 5% FBS and different concentrations of PTX, CDDP, or SN38 on 12-well plates. After a 72-h incubation, the cells were counted using a hemocytometer after the addition of trypan blue exclusion dye to determine the cell viability. In the apoptosis assay, TUNEL-positive cells were quantified as apoptotic cells by a flow cytometric analysis as described previously [22].

DNA extraction, RNA isolation, and cDNA synthesis

ES-2 cells were suspended in 0.1% SDS/Tris-EDTA buffer (pH 8.0). After treatment with proteinase K (Sigma-Aldrich) and RNase A (Invitrogen, Carlsbad, CA), phenol/chloroform extraction and ethanol precipitation were preformed to purify genomic DNA. Total RNA was isolated using TRIzol reagent (Invitrogen) according to the manufacturer’s protocol. First-strand cDNA synthesis was performed with 1 μg of total RNA using with Primerscript II reverse transcriptase (Takara Bio, Otsu, Shiga, Japan) following the manufacturer’s protocol.

Real-time quantitative PCR (qPCR)

qPCR was performed using TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA) and
the samples were analyzed by an Applied Biosystems 7500 Fast Real-time PCR system. TaqMan probes used were as follow: HB-EGF: Hs00181813_m1; AREG: Hs00950669_m1; and GAPDH: Hs02758991_g1. The methods used for the data analysis were described previously [12].

**Western blot analysis**

Whole cell lysates (5 μg) were electrophoresed through 10% SDS-PAGE gels and proteins were transferred to a polyvinylidene difluoride membrane using a semi-dry electroblot (Bio-Rad, Hercules, CA). The blot was probed with primary antibodies (anti-human SP1 antibody [#07-645; Millipore, Billerica, MA], anti-human GAPDH antibody [#ABS16; Millipore]) and secondary antibody (anti-rabbit IgG-Peroxidase [A9169; Sigma-Aldrich]), and then the binding to antibody was detected using ECL Western Blotting Detection Regents (General Electric Company, Fairfield, CT) and a Fuji image analyzer (LAS mini-3000; Fujifilm, Tokyo, Japan) according to the manufacturer’s protocol.

**ELISA**

Cells were incubated with culture medium for 24 h. After a 24-h incubation, the concentrations of HB-EGF and AREG in the culture medium were determined using a commercially available sandwich ELISA (DuoSet kit; R&D Systems) according to the manufacturer’s instructions.

**Vectors**

To generate promoter constructs for the HB-EGF gene promoter, which were located at −4138 to +205 base pair (bp), −125 to +205 bp, −178 to +205 bp, and −253 to +205 bp from its transcriptional start site (TSS), the sequences were amplified and cloned into pGL4.12 (Promega, Madison, WI). All nucleotide numbering was done with reference to the TSS. The primers used for these PCR assays are listed in Table S1. The pGL4.12 and fragments were digested with KpnI and NcoI restriction enzymes and ligated. To create pGL/HB−454/+205 and pGL/HB−4136/+205, pGL/HB−2583/+205 was digested with Ndel and KpnI or AseI and KpnI, and self-ligation was performed after blunt-ended treatment with Klenow fragment (Takara Bio). Site-detected mutants of the reporter vector were constructed by inverse PCR with primers described in Table S1. The sequences of all generated vectors were confirmed by DNA sequencing. The expression vectors for SP1 (EX-Y2188-Lv105) and EGFP (EX-EGFP-Lv105) were purchased from GeneCopoeia (Rockville, MD).

**Report assay**

The luciferase assay was performed with ES-2 cells and 293T cells. A total of 25,000 cells were incubated on 24-well plates for 16 h, and then were cotransfected with 1 μg of promoter reporter vector and 25 ng of pRL-TK (Promega), which had a renilla-luciferase gene downstream of the thymidine kinase promoter. Lipofectamine 2000 (Invitrogen) and Opti-MEM (Gibco) were used for transfection. When cells were treated with SN38, the culture medium was changed to RPMI-1640 medium supplemented with 10% FBS and SN38 (10 nmol/L). After a 48-h incubation, Dual-Luciferase Reporter Assay (Promega) was performed according to the manufacturer’s protocol.

**Small interfering RNA**

Stealth RNAi (Invitrogen) against SP1 (siSP1_1: 5’-CA AUGGCAGUGAGUCUUCCAAGAAU-3’, siSP1_2: 5’-GACAGGUCAGUUGGCAGACUCUACA-3’) and control siRNAs (Control_1: Stealth RNAi siRNA Negative Control Lo GC, Control_2: Stealth RNAi siRNA Negative Control Med GC, Invitrogen) were transfected using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s protocol.

**Chromatin immunoprecipitation assay**

ES-2 cells which were cultured until subconfluent in five 15 cm dishes were fixed in 1% formaldehyde for 10 min at 37°C. Chromatin was sheared using a Digital Sonifier S-250D (Branson, Danbury, CT) to yield DNA fragments of 300–800 bp. Nuclear extraction, immunoprecipitation, reverse cross-linking, and DNA purification were performed using Magna ChIP A kit (Millipore) according to the manufacturer’s protocol. An anti-SP1 antibody (#07-645; Millipore), tri-methyl-histone H3 (Lys4) monoclonal antibody (#9751S; Cell Signaling Technology, Boston, MA), and normal rabbit IgG (#2729S; Cell Signaling Technology) were used in the immunoprecipitation reactions. Quantitative real-time PCR was performed using SYBR Premix Ex Taq GC (Takara Bio) to detect the HB-EGF promoter fragments.

**Statistical analysis**

The two-tailed independent Student’s t-test was used to calculate all P-values. P < 0.05 was considered statistically significant.
Results

Promotion of HB-EGF expression in response to SN38 treatment

First, we examined the expression of HB-EGF and AREG in 11 cell lines of OCCC. HB-EGF was highly expressed in all of the cell lines, and eight of the 11 cell lines had a high-expression level of AREG (Fig. 1). OVTOKO and ES-2 cells had the highest expression of HB-EGF, while the OVISE and RMG-II cells had higher expression of AREG compared to that of HB-EGF.

To evaluate in vitro anticancer effects of conventional anticancer agents in the OVISE, RMG-II, OVTOKO, and ES-2 cells, cell viability assays were performed using SN38 (Fig. 2A), PTX (Fig. 2B), or CDDP (Fig. 2C). In this analysis, SN38 was a most effective anticancer agent in all four OCCC cell lines. Real-time PCR showed a twofold or higher increase in HB-EGF expression induced by the treatment of the OCCC cells with SN38, and the concentration of HB-EGF also increased more than twofold in the culture medium of RMG-II and ES-2 cells following SN38 treatment (Fig. 3A and B). In contrast, a high concentration of PTX or CDDP did not induce HB-EGF expression in ES-2 cells (Fig. 3C). The addition of the recombinant HB-EGF in cell culture blocked a decrease in cell viability with the treatment of SN38 in OCCC cells (Fig. 3D and E). These results indicated that HB-EGF plays a pivotal role in defense mechanism against the treatment of SN38 in OCCC cells.

To address the potential synergistic anticancer effects of the combination of SN38 and a specific inhibitor of HB-EGF (CRM197), apoptosis assays were performed after treating ES-2 or OVTOKO cells with SN38 and/or CRM197. Treatment with 10 μg/mL of CRM197 and 10 nmol/L of SN38 induced a marked increase in the number of apoptotic ES-2 and OVTOKO cells, compared to...
cells with SN38 treatment alone, as determined using TUNEL assay (Fig. 3F and G). These results suggested that the suppression of HB-EGF during the treatment with SN38 leads to a synergistic anticancer effect in OCCC cells.

**Screening for transcription factors that regulate the HB-EGF expression induced by SN38 treatment**

To identify transcription factor(s) that contribute to the HB-EGF induction following treatment with SN38, a promoter analysis was performed using the ES-2 cells. For the reporter gene analysis, a HB-EGF promoter fragment (−2585/+205), which is conserved among mammalian species, fused to a luciferase vector, and various truncated constructs were synthesized. The luciferase assay showed that a reporter vector containing promoter fragment of /C0 178/+205 bp from HB-EGF TSS (pGL/HB /C0 178/+205) exhibited an about 20-fold increase in luciferase activity compared to that of pGL/HB /C0 125/+205 (Fig. 4A). Additionally, treatment with SN38 induced ~twofold increase in the luciferase activity in a reporter vector containing

---

**Figure 3.** The association between HB-EGF expression and the SN38 treatment of OCCC cells. The induction of HB-EGF mRNA in cells (A) and HB-EGF protein in the culture medium (B) in OVTOKO (open bars), OVISE (diagonal striped bars), RMG-II (gray bars), and ES-2 (closed bars) cells treated with SN38 (10 nmol/L) for 12 or 24 h. Each value represents the mean (n = 3) and SD. (C) The differences in the HB-EGF mRNA expression in ES-2 cells after the treatment with SN38 (open bars), CDDP (diagonal striped bars), or PTX (gray bars). The differences in cell viabilities of RMG-II (D) and OVISE (E), which were cultured with recombinant human HB-EGF (0 and 200 pg/mL) and SN38 (0, 50, and 100 nmol/L). Each value represents the mean fold change (n = 3) and the SD. *P < 0.05. The changes in the apoptosis rate of ES-2 (F) and OVTOKO (G) cells after the treatment with each concentration of SN38 with (closed bars) or without CRM197 (10 μg/mL, diagonal striped bars). Each value represents the mean apoptosis ratio (n = 3) and SD. *P < 0.05, SN38-only versus SN38 with CRM197. HB-EGF, heparin-binding epidermal growth factor-like growth factor; PTX, paclitaxel.
Induction of HB-EGF Expression via SP1

K. Miyata et al.

(A) HB-EGF

(B) MatInspector

GTNGCNCBNn ZFP161
nSGGGGCGGGGNnn SP1
NVKGGCCGGGGBn SP1
NNGGGGCGCNNn SP1
GGCCGGGASn KLF6
nNGGGGAGGGSGnnnn ZBTB7B
nKGGAGGGGAGn MAZ
NVKGGCCGGGGBn SP1
NNGGGGCGCNNn SP1
-125 CAGCCCCCGACCGGCGGGCGGGGCAGGACTGGCCGGAGGAGGGGCGGG-178
nnnnnHACCTVBSBn KLF1
nBNBGGCCTGCGCGNn NRF1
nnnnnNVRGGGGYGGNn KLF6
GGCCYG G RE

AliBaba 2.1

-125 CAGCCCCCGACCGGCGGGCGGGGCAGGACTGGCCGGAGGAGGGGCGGG-178

=SP1==

=WT1==

=SP1==

=EGR2==

=SP1==

=GAL4==

=TEAD2==

=SP1==

=SP1==

(C)

(D)

(E)

Fold change in the relative luciferase activity (pGL 4.12 = 1.0)

Fold change in the luciferase activity (pGL 4.12 = 1.0)

Fold change in the input %

Fold change in the input %

Fold change in the input %
pGL/HB_{-178/+205} compared to the control (Fig. 4A). Accordingly, the sequence located −178 to −125 bp from the TSS of HB-EGF was recognized as a promoter sequence bound by transcription factors.

Using the MatInspector (http://www.genomatix.de) and AliBaba 2.1 (http://www.gene-regulation.com) in silico analysis programs, we found that SP1-binding sites are commonly found in this promoter sequence (Fig. 4B). Since the HB-EGF promoter has a TATA-less and GC-rich promoter, which are characteristics of SP1-binding promoters, we focused on SP1 as the candidate transcription factor inducing HB-EGF in SN38-treated ES-2 cells [17, 23, 24].

Reporter vectors with site mutations of each SP1-binding site showed significantly reduced luciferase activity compared to the control (Fig. 4C). Moreover, the luciferase activity significantly decreased, compared to the control, when the two putative binding sites of SP1 were replaced with mutant sites (Fig. 4C). Forced expression of SP1 activated the luciferase activity in 298T cells transfected with pGL/HB_{-178/+205}, although no difference was found between the forced expression of SP1 and control in 293T cells transfected by pGL/HB_{-125/+205} (Fig. 4D).

To detect direct interaction between the SP1 protein and HB-EGF promoter in ES-2 cells, a chromatin immunoprecipitation assay was performed in cells with or without treatment with SN38. Quantitative real-time PCR showed that, during treatment with SN38, the level of HB-EGF promoter bound to SP1 significantly increased compared to that of control cells (Fig. 4E). These results indicated that the HB-EGF expression promoted by the treatment with SN38 was regulated by SP1 in OCCC cells.

**Contribution of SP1 to the HB-EGF expression and SN38 sensitivity of OCCC cells**

To confirm whether SP1 affects the sensitivity of cells to SN38 via the induction of HB-EGF expression, the expression and the cell viability assays were performed after the transfection of small interfering RNA (siRNA) targeting SP1. A Western blot analysis showed that the ES-2 cells transfected with siSP1_1 and siSP1_2 had reduced expression of the SP1 protein compared to the cells transfected with control siRNAs (Fig. 5A). In the ES-2 cells transfected with siSP1_2, the HB-EGF expression was reduced to approximately half the control level, although the HB-EGF expression was not altered in the ES-2 cells transfected with siSP1_1 (Fig. 5B). No induction of HB-EGF expression was found in the presence of SN38 in the ES-2 cells transfected with either siSP1_1 or siSP1_2 (Fig. 5C). Additionally, we examined alterations in the cell viabilities using RMG-II cells, which had the least antitumor effect with the treatment of SN38. Following the treatment with SN38, the number of RMG-II cells transfected with siSP1_1 and siSP1_2 significantly decreased compared to that in the RMG-II cells transfected with control siRNAs (Fig. 6). These results indicate that SP1 regulates the drug sensitivity of SN38 by regulating the HB-EGF expression in OCCC cells.

**Discussion**

In this study, HB-EGF was attributable for the escape from cell death, as SN38 damaged OCCC cells. SP1 activated HB-EGF expression through its binding to multiple transcription sites within the promoter of HB-EGF in OCCC cells. In addition, the suppression of HB-EGF as well as SP1 enhanced the sensitivity of SN38 in OCCC cells. SP1, which belongs to the family of SP1/Kruppel-like factor (KFL) transcriptional factors, regulates the expression of numerous genes involved in cell proliferation, apoptosis, and differentiation [25]. Phorbol 12-myristate 13 acetate (PMA) induced an increase in the transcriptional activity of SP1 through the deacetylation of SP1, and also provoked the ectodomain shedding of HB-EGF; it also increased the expression of HB-EGF [26, 27].
Additionally, NF-κB induced the expression of HB-EGF, and the NF-κB and SP1 binding sequence was shown to be the same GC-rich element in colon cancer cells [16, 28]. This evidence suggests that SP1 augments the expression of HB-EGF through the deacetylation of SP1 or via an interaction with NF-κB. In mice, SP1 was reported to be directly bound to the promoter regions of HB-EGF [24]. In humans, SP1 also functions as a direct regulator for the expression of HB-EGF, possibly through various posttranslational modifications of SP1 and by interactions with other transcriptional factors.

Dysregulation of SP1 is found in many types of cancer, including ovarian, breast, and gastric cancer, for which HB-EGF is a rational therapeutic target [22, 29, 30]. The hypoxia-inducible factor 2α (HIF2α)–SP1 complex activated coagulation factor VII promoter in OCCC and estrogen receptor α also form complexes with SP1 in other types of ovarian cancer [31, 32]. Additionally, previous reports showed that activation of SP1 promoted breast cancer development and the metastasis of gastric cancer [33, 34]. On the other hand, the SP1 level was highly upregulated in patients with early stage and minimally invasive lung cancer cells and in patients with stage I lung cancer compared to that in lung cancers with high invasiveness and in patients with stage IV lung cancer [35]. These previous findings show that the significance of SP1 involvement in cancer progression has been controversial. In this study, the suppression of SP1 enhanced the sensitivity of OCCC cells to SN38. Therefore, it seems to be important that the suppression of SP1 itself, as well as the inhibition of the posttranslational modifications of SP1, are critical for cancer therapy.

Several compounds that inhibit the transcriptional activity of SP1 have been developed for cancer therapy [25], for example, arsenic trioxide downregulates the expression of SP1 [36]. A phase III trial of arsenic trioxide was performed for patients with acute promyelocytic leukemia classified as having low-to-intermediate risk, and the results suggested that all-trans-retinoic acid plus arsenic trioxide may be superior to all-trans-retinoic acid.
plus other chemotherapy [37]. Bortezomib has been already used for the treatment of patients with multiple myeloma [38, 39]. Bortezomib has been shown to decrease the expression of SP1 and disrupt the interaction of SP1 with NF-κB [40]. Other inhibitory compounds for SP1 will be clinically applied for various diseases, in addition to cancer [41, 42].

We have performed a clinical phase II trial using CRM197 in patients with recurrent and advanced ovarian cancer. To explore the importance of the posttranslational modifications of SP1 in the induction of HB-EGF expression and to search for compounds that can inhibit such modifications, a preclinical study should be performed using combination therapy with CRM197, irinotecan, and a compound that inhibits SP1, such as arsenic trioxide or bortezomib. Such a combination would likely improve the prognosis of patients with OCCC.

Acknowledgments

This work was supported in part by funds from the Central Research Institute of Fukuoka University (Fukuoka, Japan).

Conflict of Interest

None declared.

References

1. Heintz, A. P., F. Odicino, P. Maisonneuve, M. A. Quinn, J. L. Benedet, W. T. Creasman, et al. 2006. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 95(Suppl. 1):S161–S192.
2. del Carmen, M. G., M. Birrer, and J. O. Schorger. 2012. Clear cell carcinoma of the ovary: a review of the literature. Gynecol. Oncol. 126:481–490.
3. Higashiyama, S., J. A. Abraham, J. Miller, J. C. Fiddes, and M. Klagsbrun. 1991. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251:936–939.
4. Higashiyama, S., K. Lau, G. E. Besner, J. A. Abraham, and M. Klagsbrun. 1992. Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J. Biol. Chem. 267:6205–6212.
5. Elenius, K., S. Paul, G. Allison, J. Sun, and M. Klagsbrun. 1997. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J. 16:1268–1278.
6. Ellis, P. D., K. M. Hadfield, J. C. Pascall, and K. D. Brown. 2001. Heparin-binding epidermal-growth-factor-like growth factor gene expression is induced by scrape-wounding epithelial cell monolayers: involvement of mitogen-activated protein kinase cascades. Biochem. J. 354 (Pt 1):99–106.
7. Murthy, A., V. Defamie, D. S. Smookler, M. A. Di Grappa, K. Horiuchi, M. Federici, et al. 2010. Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J. Clin. Invest. 120:2731–2744.
8. Malmsten, M., M. Davoudi, B. Walse, V. Rydengård, M. Pasupuleti, M. Mörgelin, et al. 2007. Antimicrobial peptides derived from growth factors. Growth Factors 25:60–70.
9. Iwamoto, R., S. Yamazaki, M. Asakura, S. Takashima, H. Hasuwa, K. Miyado, et al. 2003. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc. Natl. Acad. Sci. USA 100:3221–3226.
10. Miyamoto, S., M. Hirata, A. Yamazaki, T. Kageyama, H. Hasuwa, H. Mizushima, Y. Tanaka, et al. 2004. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res. 64:5720–5727.
11. Yagi, H., S. Miyamoto, Y. Tanaka, K. Sonoda, H. Kobayashi, T. Kishikawa, et al. 2005. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br. J. Cancer 92:1737–1745.
12. Tanaka, Y., S. Miyamoto, S. O. Suzuki, E. Oki, H. Yagi, K. Sonoda, et al. 2005. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin. Cancer Res. 11:4783–4792.
13. Yoshizumi, M., S. Kouremanbas, D. H. Temizer, R. P. Cambria, T. Quertermous, and M. E. Lee. 1992. Tumor necrosis factor increases transcription of the heparin-binding epidermal growth factor-like growth factor gene in vascular endothelial cells. J. Biol. Chem. 267:9467–9469.
14. Cheng, C. Y., C. T. Kuo, C. C. Lin, H. L. Hsieh, and C. M. Yang. 2010. IL-1beta induces expression of matrix metalloproteinase-9 and cell migration via a c-Src-dependent, growth factor receptor transactivation in A549 cells. Br. J. Pharmacol. 160:1595–1610.
15. Ornskov, D., E. Nexo, and B. S. Sorensen. 2007. Insulin induces a transcriptional activation of epiregulin, HB-EGF and amphiregulin, by a PI3K-dependent mechanism: identification of a specific insulin-responsive promoter element. Biochem. Biophys. Res. Commun. 354:885–891.
16. Wang, F., R. Liu, S. W. Lee, C. M. Sloss, J. Couget, and J. C. Cusack. 2006. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 26:2006–2016.
17. Kanda, N., and S. Watanabe. 2005. 17 beta-estradiol enhances heparin-binding epidermal growth factor-like
growth factor production in human keratinocytes. Am. J. Physiol. Cell Physiol. 288:C813–C823.

18. Kaneto, H., J. Miyagawa, Y. Kajimoto, K. Yamamoto, H. Watada, Y. Umayahara, et al. 1997. Expression of heparin-binding epidermal growth factor-like growth factor during pancreas development. A potential role of PDX-1 in transcriptional activation. J. Biol. Chem. 272:29137–29143.

19. Chen, X., G. Raab, U. Deutsch, J. Zhang, R. M. Ezzell, and M. Klagsbrun. 1995. Induction of heparin-binding EGF-like growth factor expression during myogenesis. Activation of the gene by MyoD and localization of the transmembrane form of the protein on the myotube surface. J. Biol. Chem. 270:18285–18294.

20. Yanagibashi, T., I. Gorai, T. Nakazawa, E. Miyagi, F. Hirahara, H. Kitamura, et al. 1997. Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. Br. J. Cancer 76:829–835.

21. Uchida, T., A. M. Pappenheimer, Jr., and R. Greany. 1973. Diphertheria toxin and related proteins. I. Isolation and properties of mutant proteins serologically related to diphertheria toxin. J. Biol. Chem. 248:3838–3844.

22. Yotsumoto, F., H. Yagi, S. O. Suzuki, E. Oki, H. Tsujioka, T. Hachisuga, et al. 2008. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem. Biophys. Res. Commun. 365:555–561.

23. Wierstra, I. 2008. SP1: emerging roles—beyond constitutive activation of TATA-less housekeeping genes. Biochem. Biophys. Res. Commun. 372:1–13.

24. Edwards, J. P., X. Zhang, and D. M. Mosser. 2009. The expression of heparin-binding epidermal growth factor-like growth factor by regulatory macrophages. J. Immunol. 182:1929–1939.

25. Chang, W. C., and J. J. Hung. 2012. Functional role of post-translational modifications of Sp1 in tumorigenesis. J. Biomed. Sci. 19:94.

26. Liao, M., Y. Zhang, and M. L. Dufau. 2008. Protein kinase C alpha-induced derepression of the human luteinizing hormone receptor gene transcription through ERK-mediated release of HDAC1/Sin3A repressor complex from Sp1 sites. Mol. Endocrinol. 22:1449–1463.

27. Gechtman, Z., J. L. Alonso, G. Raab, D. E. Ingber, and M. Klagsbrun. 1999. The shedding of membrane-anchored heparin-binding epidermal-like growth factor is regulated by the Raf/mitogen-activated protein kinase cascade and by cell adhesion and spreading. J. Biol. Chem. 274:28828–28835.

28. Xu, J., W. F. Ding, K. K. Shao, X. D. Wang, G. H. Wang, H. Q. Li, et al. 2012. Transcription of promoter from the human APRIL gene regulated by Sp1 and NF-κB. Neoplasma 59:341–347.

29. Miyamoto, S., H. Yagi, F. Yotsumoto, T. Kawarabayashi, and E. Mekada. 2006. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci. 97:341–347.

30. Sanui, A., F. Yotsumoto, H. Tsujioka, T. Fukami, S. Horiuchi, K. Shirotta, et al. 2010. HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer. Anticancer Res. 30:3143–3149.

31. Koizume, S., S. Ito, and E. Miyagi. 2012. HIF2α-Sp1 interaction mediates a deacetylation-dependent FVII-gene activation under hypoxic conditions in ovarian cancer cells. Nucleic Acids Res. 40:5389–5401.

32. Kim, K., R. Barhoumi, R. Burghardt, and S. Safe. 2005. Analysis of estrogen receptor α-Sp1 interactions in breast cancer cells by fluorescence resonance energy transfer. Mol. Endocrinol. 19:843–854.

33. Gorbatenko, A., R. W. Olesen, N. Marup, G. Thiel, T. Kallunki, E. Valen, et al. 2014. ErbB2 upregulates the Na+, HCO3(−)–cotransporter NBCn1/SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Kruppel-like factor 4. FASEB J. 28:350–363.

34. Zhou, C., J. Ji, Q. Cai, M. Shi, X. Chen, Y. Yu, et al. 2013. MTA2 promotes gastric cancer cells invasion and is transcriptionally regulated by Sp1. Mol. Cancer 12:102. doi: 10.1186/1476-4598-12-102.

35. Hsu, T. I., M. C. Wang, S. Y. Chen, Y. M. Yeh, W. C. Su, W. C. Chang, et al. 2012. Sp1 expression regulates lung tumor progression. Oncogene 31:3973–3988.

36. Jutooru, I., G. Chadalapaka, S. Sreevalsan, P. Lei, R. Barhoumi, R. Burghardt, et al. 2010. Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp. Cell Res. 316:2174–2188.

37. Lo-Cocco, F., G. Avvisati, M. Vignetti, C. Thiede, S.M. Orlando, S. Iacobelli, et al. 2013. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 369:111–121.

38. San Miguel, J. F., R. Schlag, N. K. Khugaeva, M. A. Dimopoulos, O. Shpilberg, M. Kropff, et al. 2008. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359:906–917.

39. Mateos, M. V., P. G. Richardson, R. Schlag, N. K. Khugaeva, M. A. Dimopoulos, O. Shpilberg, et al. 2010. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J. Clin. Oncol. 28:2259–2266.

40. Liu, S., Z. Liu, Z. Xie, J. Pang, J. Yu, E. Lehmann, et al. 2008. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 111:2364–2373.

41. Banerjee, S., D. Kong, Z. Wang, B. Bao, G. G. Hillman, and F. H. Sarkar. 2011. Attenuation of multi-targeted
proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic. Mutat. Res. 728:47–66.
42. Chuengsamarn, S., S. Rattanamongkolgul, B. Phonrat, R. Tungtrongchitr, and S. Jirawatnotai. 2014. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoïd extract: a randomized controlled trial. KJ. Nutr. Biochem. 25:144–150.

Supporting Information
Additional Supporting Information may be found in the online version of this article:
Table S1. Primer sequences.